Elicio Therapeutics (ELTX) Leases (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Leases data on file, last reported at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 17.19% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $4.5 million (down 17.19% YoY), and the FY2025 full-year result was $4.8 million, down 16.19% from the prior year.
• Leases for Q1 2026 stood at $4.5 million, down from $4.8 million in the prior quarter.
• Across five years, Leases topped out at $7.4 million in Q4 2022 and bottomed at $126000.0 in Q1 2023.
• The 5-year median for Leases is $5.5 million (2025), against an average of $5.2 million.
• The widest annual swing landed in 2023, when Leases slumped 96.68%; it then jumped 4942.86% in 2024.
• A 5-year view of Leases shows it stood at $7.4 million in 2022, then slipped by 10.71% to $6.6 million in 2023, then decreased by 13.06% to $5.7 million in 2024, then dropped by 16.19% to $4.8 million in 2025, then slipped by 5.08% to $4.5 million in 2026.
• The last three Leases figures came in at $4.5 million (Q1 2026), $4.8 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.

Peer Comparison